WALTHAM, Mass • 2023-11-07

BostonGene and Weill Cornell Medicine to Showcase Poster Presentations on Transcriptome-based Tumor Microenvironment Classification for Advancement of Personalized Cancer Therapeutics at the 20th International Cancer Genome Consortium Scientific Workshop

5 min to read

BostonGene, a leading provider of AI-driven molecular and immune profiling solutions today announced that three research studies done in collaboration with Weill Cornell Medicine
WALTHAM, Mass – November 7, 2023 - BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, today announced that three research studies done in collaboration with Weill Cornell Medicine will be presented as poster presentations at the 20th International Cancer Genome Consortium (ICGC) Scientific Workshop/ 7th Accelerating Research in Genomic Oncology (ARGO) meeting. The event, scheduled for November 7 - 9 in New York, is hosted by Weill Cornell Medicine’s Englander Institute for Precision Medicine and will provide updates on genomic profiling of cancers and underscore the global mission to eradicate the burden of cancer.

Details of the presentations are as follows:

Title: Reconstruction of the Metastatic Castration-Resistant Prostate Tumor Microenvironment with Comprehensive Profiling Reveals Unique Subtypes
Presenter: Ahmed Elsaeed, MD, Weill Cornell Medicine

Metastatic castration-resistant prostate cancer (mCRPC) that is not dependent on the androgen receptor accounts for approximately 25-30% of fatal prostate cancer cases. In this study, BostonGene's transcriptome-based tumor microenvironment (TME) classification approach identified five previously unidentified subtypes in both a meta-cohort and an independent cohort. These subtypes exhibit distinct molecular features and are linked to histological traits, sample origins, and clinical information, thereby offering the potential for enhanced molecular stratification with clinical-pathological relevance.

Research conducted in collaboration with Weill Cornell Medicine

Title: Reconstruction of the Glioblastoma (GBM) Tumor Microenvironment (TME) with Comprehensive Profiling Reveals Unique Subtypes
Presenter: Majd Al Assaad, MD, Weill Cornell Medicine

Understanding tumor heterogeneity is critical to improve cancer therapies in glioblastoma (GBM), the most common primary brain cancer in adults. Using transcriptomic profiling, five novel tumor microenvironment (TME) subtypes were identified in a GBM meta-cohort and an independent cohort. These subtypes are characterized by variations in gene expression and cellular composition and are linked to histological features, sample origins, and clinical prognosis.

Research conducted in collaboration with Weill Cornell Medicine

Title: The intratumor Microbiome Profile in Prostatic Adenocarcinoma is Consistent within Different Metastatic Sites
Presenter: Jeremy Miyauchi, MD, Weill Cornell Medicine 

The tumor microbiome is composed of tumor-type-specific intracellular bacteria and may be associated with cancer progression and resistance to chemotherapy. An analysis of microbiome using RNAseq revealed strong correlations among microbiomes across different metastatic tumor sites within prostate cancer patients. Characterizing microbiome profiles in different sites can aid in treatment selection and help to understand clinical outcomes.

Research conducted in collaboration with Weill Cornell Medicine

Click here to learn more about the 20th International Cancer Genome Consortium Scientific Workshop/ 7th Accelerating Research in Genomic Oncology (ARGO) meeting.

About BostonGene Corporation

BostonGene has a mission to provide transformative, AI-integrated molecular analytics and biomarker discovery for precision matching of therapies to improve the lives of patients living with cancer and other immune-related diseases. BostonGene’s service model provides customized client solutions using a multi-omic approach prioritized for real-world impact, including optimized standard-of-care therapies, accelerated research and cost-effective, measurable results. BostonGene’s tests reveal key drivers of each patient’s unique disease profile, including an in-depth profile of the immune microenvironment, actionable mutations, biomarkers of response to diverse therapies, and recommended therapies. Through these comprehensive analyses, BostonGene’s tests generate a personalized roadmap for therapeutic decision-making for each patient. For more information, visit BostonGene at http://www.BostonGene.com.

Erin O’Reilly

Senior Director

+1-617-283-2285

Erin.Oreilly@BostonGene.com